Altimmune (ALT) Change in Accured Expenses (2010 - 2026)

Altimmune (ALT) has reported Change in Accured Expenses for 17 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 46.73% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at $1.6 million (up 68.96% YoY), while the FY2025 annual figure was $2.4 million, up 2233.04% from the prior year.
• Change in Accured Expenses fell to -$2.5 million in Q1 2026 per ALT's latest filing, from $4.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.4 million in Q3 2022 and bottomed at -$4.7 million in Q3 2024.
• Historically, Change in Accured Expenses has averaged $193764.7 across 5 years, with a median of -$365000.0 in 2025.
• On a YoY basis, Change in Accured Expenses climbed as much as 338.47% in 2024 and fell as far as 392.0% in 2024.
• Altimmune's Change in Accured Expenses stood at -$2.2 million in 2022, then surged by 165.82% to $1.4 million in 2023, then jumped by 66.55% to $2.4 million in 2024, then jumped by 83.59% to $4.4 million in 2025, then slumped by 157.3% to -$2.5 million in 2026.
• Business Quant data shows ALT's Change in Accured Expenses at -$2.5 million in Q1 2026, $4.4 million in Q4 2025, and $102000.0 in Q3 2025.